144 related articles for article (PubMed ID: 24729566)
1. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.
Soussi T; Leroy B; Taschner PE
Hum Mutat; 2014 Jun; 35(6):766-78. PubMed ID: 24729566
[TBL] [Abstract][Full Text] [Related]
2. Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing.
Tikkanen T; Leroy B; Fournier JL; Risques RA; Malcikova J; Soussi T
Hum Mutat; 2018 Jul; 39(7):925-933. PubMed ID: 29696732
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B; Anderson M; Soussi T
Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
[TBL] [Abstract][Full Text] [Related]
4. Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm.
Soussi T
Hum Mutat; 2014 Jun; 35(6):643-53. PubMed ID: 24478183
[TBL] [Abstract][Full Text] [Related]
5. The TP53 gene network in a postgenomic era.
Soussi T
Hum Mutat; 2014 Jun; 35(6):641-2. PubMed ID: 24753184
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Soussi T
Adv Cancer Res; 2011; 110():107-39. PubMed ID: 21704230
[TBL] [Abstract][Full Text] [Related]
7. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
8. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering.
Soussi T; Leroy B; Devir M; Rosenberg S
Hum Mutat; 2019 May; 40(5):516-524. PubMed ID: 30720243
[TBL] [Abstract][Full Text] [Related]
11. The UMD TP53 database and website: update and revisions.
Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C; Soussi T
Hum Mutat; 2006 Jan; 27(1):14-20. PubMed ID: 16278824
[TBL] [Abstract][Full Text] [Related]
12. MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.
Soussi T; Hamroun D; Hjortsberg L; Rubio-Nevado JM; Fournier JL; Béroud C
Hum Mutat; 2010 Sep; 31(9):1020-5. PubMed ID: 20572016
[TBL] [Abstract][Full Text] [Related]
13. Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
Donehower LA
Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648
[TBL] [Abstract][Full Text] [Related]
14. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Bouaoun L; Sonkin D; Ardin M; Hollstein M; Byrnes G; Zavadil J; Olivier M
Hum Mutat; 2016 Sep; 37(9):865-76. PubMed ID: 27328919
[TBL] [Abstract][Full Text] [Related]
15. Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
[TBL] [Abstract][Full Text] [Related]
16. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
[TBL] [Abstract][Full Text] [Related]
17. Recommended Guidelines for Validation, Quality Control, and Reporting of
Leroy B; Ballinger ML; Baran-Marszak F; Bond GL; Braithwaite A; Concin N; Donehower LA; El-Deiry WS; Fenaux P; Gaidano G; Langerød A; Hellstrom-Lindberg E; Iggo R; Lehmann-Che J; Mai PL; Malkin D; Moll UM; Myers JN; Nichols KE; Pospisilova S; Ashton-Prolla P; Rossi D; Savage SA; Strong LC; Tonin PN; Zeillinger R; Zenz T; Fraumeni JF; Taschner PE; Hainaut P; Soussi T
Cancer Res; 2017 Mar; 77(6):1250-1260. PubMed ID: 28254861
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries.
Carbonnier V; Leroy B; Rosenberg S; Soussi T
Sci Rep; 2020 Nov; 10(1):20368. PubMed ID: 33230179
[TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
20. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
